| 477.1 -4.6 (-0.95%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 592.68 | 1-year : | 623.32 |
| Resists | First : | 507.43 | Second : | 533.66 |
| Pivot price | 480.15 |
|||
| Supports | First : | 465 | Second : | 386.88 |
| MAs | MA(5) : | 482.3 |
MA(20) : | 486.72 |
| MA(100) : | 456  |
MA(250) : | 441.19 |
|
| MACD | MACD : | 1.5 |
Signal : | 3.4 |
| %K %D | K(14,3) : | 46.2 |
D(3) : | 43.8 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 533.66 | Low : | 362.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VRTX ] has closed above bottom band by 33.8%. Bollinger Bands are 56.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 481.69 - 484.59 | 484.59 - 486.74 |
| Low: | 462.96 - 466.8 | 466.8 - 469.65 |
| Close: | 472.03 - 477.73 | 477.73 - 481.97 |
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Wed, 29 Jul 2026
Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued? - Yahoo Finance
Wed, 29 Jul 2026
Vertex Pharmaceuticals (VRTX) Stock Looks Like A Bargain At This Price - Yahoo Finance
Wed, 29 Jul 2026
AbCellera, Vertex Pharma ink drug discovery deal (ABCL:NASDAQ) - Seeking Alpha
Wed, 29 Jul 2026
Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Wed, 29 Jul 2026
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout - ChartMill
Tue, 28 Jul 2026
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 254 (M) |
| Shares Float | 253 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 100 (%) |
| Shares Short | 4,990 (K) |
| Shares Short P.Month | 4,620 (K) |
| EPS | 16.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 76.18 |
| Profit Margin | 35.5 % |
| Operating Margin | 38.1 % |
| Return on Assets (ttm) | 12.1 % |
| Return on Equity (ttm) | 24.2 % |
| Qtrly Rev. Growth | 7.8 % |
| Gross Profit (p.s.) | 26.2 |
| Sales Per Share | 48.14 |
| EBITDA (p.s.) | 19.62 |
| Qtrly Earnings Growth | 61.4 % |
| Operating Cash Flow | 4,240 (M) |
| Levered Free Cash Flow | 2,780 (M) |
| PE Ratio | 28.31 |
| PEG Ratio | 1.6 |
| Price to Book value | 6.26 |
| Price to Sales | 9.9 |
| Price to Cash Flow | 28.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|